Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The role of high-dose corticosteroids in the treatment of chronic lymphocytic leukemia.

Expert opinion on investigational drugs - 1 Jul 2012

Smolej Lukáš

Abstract excerpt

INTRODUCTION: Management of refractory chronic lymphocytic leukemia (CLL) represents a major challenge because of the poor prognosis and limited treatment options. While corticosteroids have been used to treat CLL since 1940s, their benefit has never been conclusively proved. Recently, several groups reported use of high-dose corticosteroids (methylprednisolone or dexamethasone) either alone or combined with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Dose-Response Relationship, Drug

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Genes, p53

Share to Glucocorticoids

Share to Leukemia, Lymphocytic, Chronic, B-Cell

Share to Mutation

Share to Treatment Outcome

Source

Identifiers

PMID: 22616646
DOI: 10.1517/13543784.2012.690393

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The role of high-dose corticosteroids in the treatment of chronic lymphocytic leukemia.PMID 22616646Read ↗

Ofatumumab added to dexamethasone in patients with relapsed or refractory chronic lymphocytic leukemia: Results from a phase II study.Semantic proximity Read ↗

Update on therapy of chronic lymphocytic leukemia.Semantic proximity Read ↗

Targeting inflammatory pathways in chronic lymphocytic leukemia.Semantic proximity Read ↗

Dose-dense high-dose methylprednisolone and rituximab in the treatment of relapsed or refractory high-risk chronic lymphocytic leukemia.Semantic proximity Read ↗

Clinico-Biological Implications of Modified Levels of Cytokines in Chronic Lymphocytic Leukemia: A Possible Therapeutic RoleSemantic proximity Read ↗

Modern treatment in chronic lymphocytic leukemia: impact on survival and efficacy in high-risk subgroups.Semantic proximity Read ↗

Campath-1H (anti-CD52) monoclonal antibody therapy in lymphoproliferative disorders.Semantic proximity Read ↗

Antibody therapy for chronic lymphocytic leukemia.Semantic proximity Read ↗

Lenalidomide and rituximab for the initial treatment of patients with chronic lymphocytic leukemia: a multicenter clinical-translational study from the chronic lymphocytic leukemia research consortium.Semantic proximity Read ↗

Chronic lymphocytic leukemia. Preclinical oral poster session.Semantic proximity Read ↗

The management of chronic lymphocytic leukemia--a case history.Semantic proximity Read ↗

NOTCH1 mutations identify a chronic lymphocytic leukemia patient subset with worse prognosis in the setting of a rituximab-based induction and consolidation treatment.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.